5 completed, 5 unknown, 4 recruiting, 3 terminated. 22 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 5, Unknown 5, Recruiting 4, Terminated 3, Active not recruiting 2, Not yet recruiting 2, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow TP protocol: new trials by email Literature Review of TP protocol trials Research Report on TP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor, Retlirafusp alfa / Indole-3-carbinol + Black garlic fermentation extract / Lactobacillus rhamnosus / Placebo + Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor - Valid MeSH Conditions | Phase 2 | Not yet recruiting | Sun Yat-sen University | 347 | 2026-07-07 | 2026-07-16 |
| Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin - Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | West China Hospital | 20 | 2024-12-01 | 2024-12-03 |
| BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma BTLA inhibitor (JS004), Toripalimab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Henan Provincial People's Hospital | 20 | 2024-09-30 | 2024-09-19 |
| Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy) - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 90 | 2024-07-11 | 2026-10-29 |
| Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma Paclitaxel and Cisplatin, Cadonilimab, Radiotherapy - Endometrial Neoplasms, Neoplasm Recurrence, Local | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 30 | 2024-06-13 | 2026-04-24 |
| Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy - Esophagus Cancer | Phase 2 | Active not recruiting | Sun Yat-sen University | 46 | 2024-03-02 | 2026-04-23 |
| Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab） - Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Qingdao Central Hospital | 90 | 2023-09-20 | 2024-07-24 |
| Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma Adebrelimab, TP regimen, Surgery or radiotherapy - Squamous Cell Carcinoma of Head and Neck | Phase 2 | Recruiting | Xiuping Ding | 69 | 2023-04-01 | 2025-07-09 |
| Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Paclitaxel, Cisplatin, tislelizumab, Radiotherapy - Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Sun Yat-sen University | 114 | 2022-09-15 | 2024-11-18 |
| Neoadjuvant Immunotherapy to ESCC Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin - Esophagus SCC | Phase 2 | Withdrawn | Qilu Hospital of Shandong University | 2020-12-01 | 2022-04-26 | |
| AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer AT regimen, TP regimen - HER2-negative Breast Cancer | Phase 2 | Unknown | Sichuan Provincial People's Hospital | 100 | 2020-08-01 | 2020-08-05 |
| Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer Toripalimab, Paclitaxel/Cisplatin, Intensity-modulated radiotherapy - Unresectable Esophageal Cancer | Phase 2 | Completed | Mian XI | 42 | 2019-06-25 | 2022-08-23 |
| Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer Toripalimab, Paclitaxel/cisplatin, Intensity-modulated radiotherapy - Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Resectable Esophageal Cancer | Phase 2 | Unknown | Jianhua Fu | 44 | 2019-06-25 | 2019-12-26 |
| KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma KN046, palliative radiotherapy - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Chest Hospital | 100 | 2019-05-22 | 2019-05-29 |
| Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer S-1 and Paclitaxel, Paclitaxel and Cisplatin, 5-FU and Cisplatin - Esophageal Cancer | Phase 2 / Phase 3 | Terminated | Peking University | 4 | 2012-08-01 | 2017-04-07 |
| Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Icotinib, intensity-modulated radiotherapy, Paclitaxel and Cisplatin - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Completed | Taizhou Hospital | 48 | 2012-02-01 | 2018-04-17 |
| A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma Cetuximab,Paclitaxel,Cisplatin - Oral Cancer | Phase 2 | Completed | National Health Research Institutes, Taiwan | 47 | 2009-09-01 | 2016-05-04 |
| Paclitaxel and Cisplatin for Thymic Neoplasm paclitaxel and cisplatin - Thymoma, Thymic Carcinoma | Phase 2 | Terminated | Korean Cancer Study Group | 39 | 2008-09-01 | 2013-04-12 |
| A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer Paclitaxel & Cisplatin, Mycobacterium w. - Non Small Cell Lung Cancer | Phase 2 | Completed | Cadila Pharnmaceuticals | 221 | 2008-06-01 | 2012-08-07 |
| Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma paclitaxel; cisplatin - Esophageal Cancer | Phase 2 | Completed | Chinese Academy of Medical Sciences | 43 | 2007-12-01 | 2015-04-14 |
Showing 20 of 22. Sign in to see all of them.
Esophageal Squamous Cell Carcinoma (10) · Esophageal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Mouth Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Neoplasm Recurrence, Local (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pathologic Complete Response (1) · Thymic epithelial tumor (1)
Sun Yat-sen University (3) · Chinese Academy of Medical Sciences (2) · Cadila Pharnmaceuticals (1) · Fujian Medical University Union Hospital (1) · Henan Provincial People's Hospital (1) · Jianhua Fu (1) · Korean Cancer Study Group (1) · Mian XI (1) · National Health Research Institutes, Taiwan (1) · Peking University (1) · Qilu Hospital of Shandong University (1) · Qingdao Central Hospital (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Chest Hospital (1) · Sichuan Provincial People's Hospital (1)
China (17) · India (1) · South Korea (1) · Taiwan (1) · United States (1)
A. Rajkumar, MD (1) · A.K. Patel, MD (1) · Aloke G Dastidar, MD (1) · Anup Majumdar, MD (1) · Apurva Patel, MD (1) · Ashutosh N Aggarwal, MD (1) · Chanchal Goswami, MD (1) · Chao Zhou, MD. (1) · Dae Seog Heo, MD, PhD (1) · Haihua Yang, MD. (1) · J Y Chang, M.D. (1) · Jaydip Biswas, MD (1) · Jianhua Fu, MD (1) · Jing Huang, M.D (1)
PMID 36990609, PMID 17928611, PMID 20700125, PMID 28317872, PMID 30642373, PMID 34454674, PMID 34519801, PMID 35108470, PMID 37560259, PMID 37797632, PMID 37852261, PMID 39235488, PMID 39281099, PMID 41962116